Salmon Poisoning Therapeutics Market Size, Share, and Growth Forecast 2026 - 2033

The global salmon poisoning therapeutics market size is likely to be valued at US$172.4 million in 2026 and is estimated to reach US$331.7 million by 2033, growing at a CAGR of 9.8% during the forecast period from 2026 to 2033, driven by the rising recognition of fish-associated infections in dogs, surging exposure to raw or undercooked salmonids, and increasing veterinary adoption of rapid diagnostic and targeted treatment approaches.

Driver - Outdoor Exposure to Increase Infection Risk

Rising interaction between dogs and rivers, streams, fishing areas, and wilderness environments can increase opportunities for exposure to infected salmonids. The disease is particularly associated with the Pacific Northwest, where salmon and trout can carry the Nanophyetus salmincola fluke.

A 2025 UC Davis case showed that a dog did not need to consume a fish directly; contact with a dead salmon during an outdoor trip was enough to raise suspicion of infection. This supports demand for rapid veterinary treatment when dogs develop fever, vomiting, diarrhea, weakness, or enlarged lymph nodes after fish exposure.

Raw Fish Feeding to Raise Canine Exposure

Feeding dogs raw or undercooked fish creates another route for exposure to infected flukes. UC Davis specifically advises owners not to feed dogs raw or undercooked freshwater fish owing to the risk of salmon poisoning and other fish-borne problems.

As raw-food feeding remains part of some pet diets, veterinarians have a greater need to recognize fish-associated infections and initiate treatment quickly. This supports demand for established therapies such as doxycycline and praziquantel when salmon poisoning is suspected.

Restraint - Severe Digestive Effects May Complicate Treatment

Severe gastrointestinal involvement can make treatment more difficult as affected dogs may develop persistent vomiting, diarrhea, dehydration, electrolyte disturbances, and loss of appetite. These problems can prevent dogs from retaining oral medicines and may require hospitalization, IV fluids, antiemetics, and sometimes additional supportive care. Current veterinary guidance specifically recommends IV doxycycline for patients with severe vomiting when available.

Earlier clinical research also documented hospitalization and supportive-care requirements among affected dogs. This raises treatment complexity and can increase the need for intensive veterinary management rather than simple outpatient drug therapy. Doxycycline itself can also cause gastrointestinal adverse effects in some dogs, requiring careful administration and monitoring.

Opportunity - Dual-pathogen Research to Help Improve Treatment Decisions

Research into related pathogens could create an opportunity for more precise diagnosis and treatment. Oregon State University researchers previously identified the “SF agent,” associated with Stellanchasmus falcatus, in salmonid fish. The organism can produce illness in dogs that resembles salmon poisoning, but it is distinct from N. helminthoeca.

This finding highlights the need to distinguish different fish-associated infections when dogs present with similar symptoms. Future pathogen-specific diagnostics could help veterinarians select treatment more accurately and reduce empirical therapy.

PCR Testing to Speed up Confirmation

Molecular testing provides another opportunity to improve management. Traditional diagnosis can involve detecting Nanophyetus eggs in feces or identifying organisms in lymph-node samples, but these methods can be difficult depending on the stage of infection.

Published veterinary research has already demonstrated PCR-based detection of N. helminthoeca, while current MSD guidance recognizes PCR assays as part of the diagnostic approach. Rising use of rapid molecular diagnostics could allow treatment to begin sooner in dogs with compatible clinical signs and a history of fish exposure.

Therapy Type Insights

Antimicrobial therapy is predicted to lead with a share of about 56.8% in 2026, as it targets Neorickettsia helminthoeca, the bacterium responsible for the systemic disease. Doxycycline and other tetracyclines are established treatments, with current Merck Veterinary Manual guidance identifying doxycycline as the treatment of choice and recommending treatment for at least seven days. This makes antimicrobial therapy the core component of disease management rather than an optional adjunct. The rapid response also supports its importance: clinical signs typically begin improving within about 24 hours after antimicrobial therapy is initiated. In dogs with severe vomiting that prevents oral medication, intravenous doxycycline can be used when available, allowing antimicrobial treatment to continue even in more advanced cases.

Supportive therapy is estimated to be the fastest-growing type in the forecast period, as salmon poisoning disease can cause severe gastrointestinal losses and systemic complications that require management in addition to eliminating the infection. Vomiting and diarrhea are common, and affected dogs can develop significant dehydration, electrolyte abnormalities, weakness, weight loss, and thrombocytopenia. Consequently, veterinary treatment can involve IV fluids, fluid resuscitation, antiemetics, electrolyte management, nutritional support, and, in particularly severe cases, blood or plasma products.

Drug Insights

Doxycycline is anticipated to dominate with a share of around 34.2% in 2026, as it is specifically identified as the treatment of choice for salmon poisoning disease. The drug addresses the Neorickettsia infection and is used as the principal antimicrobial intervention once the disease is suspected. Merck Veterinary Manual recommends oral doxycycline for at least seven days and also describes IV administration for dogs with severe vomiting. This flexibility is important as salmon poisoning disease frequently produces gastrointestinal symptoms that can make oral administration difficult.

Praziquantel is expected to be the fastest-growing application over the forecast period, as it addresses the parasitic component associated with salmon poisoning disease. The bacterium N. helminthoeca is carried by the trematode Nanophyetus salmincola, which infects dogs through consumption of infected raw or undercooked fish. Praziquantel is therefore used alongside antimicrobial therapy to eliminate the trematode. Current Merck guidance recommends praziquantel to help improve gastrointestinal signs and limit shedding of trematode eggs.

North America Salmon Poisoning Therapeutics Market Trends

North America is predicted to dominate in 2026 globally with a share of approximately 47.4%, as the region contains the principal established zone for salmon poisoning disease. The disease is particularly prevalent from northern California through Oregon and Washington to Puget Sound, with cases also occurring along inland rivers used by migrating salmon. This concentration creates an exponential demand for veterinary diagnosis and treatment than in most other regions. The presence of established clinical protocols also supports demand. Current MSD guidance recommends doxycycline as the treatment of choice, along with praziquantel and supportive care for appropriate cases.

U.S. Salmon Poisoning Therapeutics Market Trends

In North America, a share of nearly 76.4% is expected to be held by the U.S. in 2026, exhibiting the concentration of the disease across the Pacific Northwest. Northern California, Oregon, and Washington form the core U.S. disease area, while infected fish can also move the exposure risk inland through salmon migration routes. The U.S. also has relatively strong veterinary awareness of salmon poisoning, which helps clinicians connect symptoms such as fever, vomiting, diarrhea, weight loss, and enlarged lymph nodes with recent fish exposure. MSD reports that clinical signs generally improve within 24 hours after antimicrobial treatment begins, making rapid recognition particularly important.

Canada Salmon Poisoning Therapeutics Market Trends

A regional share of nearly 23.6% is predicted to be held by Canada in 2026, with demand concentrated mainly in southern British Columbia. The region shares salmon-bearing waterways and ecological conditions with the Pacific Northwest, creating an environment where the parasite and its bacterial pathogen can occur. A 2026 CDC risk assessment specifically identifies southern British Columbia as part of the geographic distribution of Nanophyetus salmincola and Neorickettsia helminthoeca. However, Canada’s opportunity remains considerably smaller than the U.S. market as the principal disease concentration is south of the Canadian border.

East Asia Salmon Poisoning Therapeutics Market Trends

East Asia is anticipated to be the fastest-growing region globally in 2026 with a share of around 20.5%, as eastern Russia and Siberia are recognized areas for Nanophyetus infection. Nanophyetus salmincola and related forms have been documented in eastern Russia, where the parasite's life cycle is linked to freshwater snails and salmonid fish. However, the evidence for widespread canine salmon poisoning disease in East Asia remains limited compared with the Pacific Northwest of North America. Hence, growth in this region is more likely to come from greater veterinary awareness, improved recognition of fish-borne infections, and better diagnostic testing rather than from a large established treatment base.

Russia Salmon Poisoning Therapeutics Market Trends

Russia will likely lead in East Asia in 2026 with a share of about 43.2%. It is an important country for salmon poisoning-related therapeutics as the Nanophyetus salmincola–Neorickettsia helminthoeca system is documented in eastern Russia. In Russia, Nanophyetus infection is mainly associated with the Amur and Ussuri River basins and Sakhalin Island. The CDC notes that nanophyetiasis is commonly detected in people in these areas.

Siberia Salmon Poisoning Therapeutics Market Trends

In 2026, Siberia is projected to account for a share of just about 29.5% in East Asia, as Nanophyetus salmincola, commonly known as the salmon poisoning fluke, is documented in Siberia and other parts of the Pacific-facing northern regions. The parasite has a complex life cycle involving snails and salmonid fish, which means areas with suitable freshwater ecosystems can support its transmission. The current Merck Veterinary Manual lists Siberia among the regions where N. salmincola occurs in dogs, cats, and other fish-eating mammals.

Latin America Salmon Poisoning Therapeutics Market Trends

Latin America will witness a steady growth over the forecast period with a share of roughly 15.5% in 2026 globally. The key evidence comes from Brazil, where researchers confirmed N. helminthoeca infection in dogs. This is important as salmon poisoning had historically been associated mainly with the U.S. and northwestern Canada.

Brazil Salmon Poisoning Therapeutics Market Trends

Brazil is predicted to register a substantial share of approximately 55.4% in 2026 in Latin America, as confirmed N. helminthoeca infection has been reported in the country’s dogs. A CDC-published investigation examined 20 dogs with pathological lesions consistent with salmon poisoning disease and identified N. helminthoeca DNA in two dogs from Maringá, Paraná. One dog's sequences were confirmed to be consistent with N. helminthoeca, and the researchers described this as the first confirmed detection of the organism outside the previously recognized endemic area.

The global salmon poisoning therapeutics market is highly fragmented and niche, with no major pharmaceutical company known to have a dedicated salmon-poisoning product franchise. Treatment relies mainly on established veterinary antibiotics, particularly doxycycline, together with praziquantel and supportive care. Competition is driven more by availability of established veterinary drugs and generic formulations than by proprietary salmon-poisoning therapies.

The competitive environment hence includes large animal-health companies, veterinary pharmaceutical manufacturers, generic-drug suppliers, and veterinary distributors. Companies with broad canine antimicrobial or antiparasitic portfolios can participate in treatment without having a product specifically labeled for salmon poisoning. There is also room for differentiation through easier dosing, injectable formulations, veterinary diagnostics, and integrated treatment protocols.

Key Industry Developments:

• In June 2026, the MSD Veterinary Manual updated its broad veterinary guidance on Nanophyetus salmincola, describing its life cycle through snails, salmonid fish, and fish-eating mammals. The update reinforces the importance of understanding the parasite's geographic distribution when assessing dogs with compatible clinical signs.
• In April 2025, UC Davis Veterinary Medicine published updated educational guidance on salmon poisoning disease in dogs, emphasizing exposure to raw or undercooked salmonids and the need for prompt veterinary treatment. The guidance also noted that the disease remains concentrated in the Pacific Northwest and that early treatment has a high success rate.
• In March 2025, UC Davis Veterinary Medicine reported a clinical case of a seven-year-old Labrador retriever that developed salmon poisoning after exposure to a dead salmon near the Smith River in northern California. The case highlighted how outdoor exposure history can help veterinarians recognize the disease when initial tests are inconclusive. The dog eventually recovered after treatment at the UC Davis veterinary hospital.